Search Results
Viewing: 10781-10790 of 11568 | All
Article
Contact Information
Our main number is (614) 722-2000 or (800) 792-8401. You may also visit our Frequently Called Numbers page for additional contact information. To send mail to a patient, please use the following address: Nationwide Children's Hospital Attn: Patient Name & Room Number 700 Children's Drive
Article
FDA Approval
The FDA has issued an accelerated approval for a second gene therapy developed at Nationwide Children's Hospital, bringing hope to children with Duchenne muscular dystrophy.
Resources & Educational Opportunities
Suicide affects people of all backgrounds. Although the prevalence of mental health disorders and rates of suicide increase as children grow older, even young children express thoughts of suicide and have died by suicide. However, there is hope.
Article
Research Staff Careers
The research we do here at Nationwide Children's impacts how we care for patients from Ohio and from around the world.
Article
Research Faculty Careers
The Abigail Wexner Research Institute (AWRI) at Nationwide Children’s is ranked among the top 10 freestanding children’s hospitals based on NIH funding. On a continuing trajectory of rapid growth, AWRI is looking for new faculty to drive the next generation of discovery at Nationwide Children's.
Specialty
Steve and Cindy Rasmussen Institute for Genomic Medicine
The Steve and Cindy Rasmussen Institute for Genomic Medicine combines a robust clinical laboratory with genome scientists and clinical geneticists to optimize patient care.
News
FDA Approves First Gene Therapy Treatment for SMA Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its approval of Zolgensma® for spinal muscular atrophy (SMA) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
News
FDA Approves First Gene Therapy Treatment for Duchenne Muscular Dystrophy Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its accelerated approval of SRP-9001/ELEVIDYS for Duchenne muscular dystrophy (DMD) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
Provider
Kevin M Flanigan
Kevin M. Flanigan, MD, is an attending neurologist at Nationwide Children's and director of the Jerry R. Mendell Center for Gene Therapy in the Abigail Wexner Research Institute at Nationwide Children's Hospital.